Prostate Cancer Study 2024 Julee Maressa The american cancer society estimated that there would be 288,300 new cases of prostate cancer and 34,700 deaths from prostate cancer in the united states in 2023. 1 within 10 years after. The study also found that the new treatment approach did not delay the recovery of testosterone levels, which is crucial for maintaining overall health and quality of life in men. “this is an important trial for men with aggressive prostate cancer who have cancer progression after both radical prostatectomy and salvage radiation therapy.
Prostate Cancer Study 2024 Julee Maressa Results from a prospective trial (nct04307056) presented at the 2024 aua annual meeting showed that treating patients with localized prostate cancer with high intensity focused ultrasound (hifu) led to noninferior salvage treatment free survival (stfs) vs radical prostatectomy. 1. stfs outcomes generally appeared to be comparable between the. The study included 505 patients with high risk prostate cancer who had clinical stage t3 or t4 disease, a gleason score of 8 or higher, or prostate specific antigen levels of 20 ng ml or higher. Active surveillance (as) is recognized as the preferred management strategy for low risk prostate cancer (pca), and it is endorsed by multiple professional clinical practice guidelines [1,2,3. The onset of castration resistance is associated with dismal outcomes in patients with prostate cancer (pca). metastasis directed therapy has been investigated in multiple disease settings and may.
Comments are closed.